Traditional Protein-A purification processes employ a costly capture step to remove host cell proteins and DNA with little removal of PRIs, thus shifting the burden downstream to removal of PRIs (e.g., using HIC, SEC), often with substantial loss of yield. With this comes the greater downstream challenge of maintaining sufficient resin capacity while being able to remove product-related impurities (PRIs e.g., aggregates, half-antibodies, misfolded antibody forms). Monoclonal antibodies and Fc fusion proteins are being produced in cell culture in ever increasing quantities. complexation chromatography, chelation chromatography, metal interaction chromatography B01D2015/3838- Ligand exchange chromatography, e.g.C07K1/165- Extraction Separation Purification by chromatography mixed-mode chromatography.complexation, chelation or metal interaction chromatography B01D15/3828- Ligand exchange chromatography, e.g.chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36 chromatography characterised by the separation mechanism B01D15/00- Separating processes involving the treatment of liquids with solid sorbents Apparatus therefor.B01- PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL. ![]() C07K1/22- Affinity chromatography or related techniques based upon selective absorption processes.C07K1/16- Extraction Separation Purification by chromatography.C07K1/14- Extraction Separation Purification.processes for the organic chemical preparation of peptides or proteins of any length C07K1/00- General methods for the preparation of peptides, i.e.DWRYENRMTFNVSR-UHFFFAOYSA-N OC(C)COC(C)COC(C)COC(C)COC(C)COC(C)O Chemical compound OC(C)COC(C)COC(C)COC(C)COC(C)COC(C)O DWRYENRMTFNVSR-UHFFFAOYSA-N 0.000 description 1.Application granted granted Critical Publication of US9127043B2 publication Critical patent/US9127043B2/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GRONKE, ROBERT S., ZAANONI, HECTOR Assigned to BIOGEN MA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US15785009P external-priority Application filed by Biogen MA Inc filed Critical Biogen MA Inc Priority to US13/254,697 priority Critical patent/US9127043B2/en Publication of US20120053325A1 publication Critical patent/US20120053325A1/en Assigned to BIOGEN IDEC MA INC. Original Assignee Biogen MA Inc Priority date (The priority date is an assumption and is not a legal conclusion. ![]() Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) GRONKE Héctor Zaanoni Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number US13/254,697 Other versions US20120053325A1 ![]() Google Patents Purification of immunoglobulinsÄownload PDF Info Publication number US9127043B2 US9127043B2 US13/254,697 US201013254697A US9127043B2 US 9127043 B2 US9127043 B2 US 9127043B2 US 201013254697 A US201013254697 A US 201013254697A US 9127043 B2 US9127043 B2 US 9127043B2 Authority US United States Prior art keywords daltons peg contaminants antibody protein Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US9127043B2 - Purification of immunoglobulins US9127043B2 - Purification of immunoglobulins
0 Comments
Leave a Reply. |